Abbott paclitaxel
Executive Summary
NaPro will supply bulk drug and license its paclitaxel related patents, including 12 issued and nine pending U.S. patents to Abbott under a development agreement. Abbott will be responsible for formulation, regulatory submissions, and marketing of the paclitaxel product. NaPro will participate in the conduct of clinical trials, which have begun recruiting, and received milestone payments and royalties. The agreement covers U.S. and Canada